Semaglutide Reduces Drinking and Withdrawal Anxiety-Like Behaviors in Rats
Semaglutide reduced alcohol intake and anxiety-like behaviors during withdrawal in rats, supporting further research—not a new treatment recommendation.
Summary
Semaglutide, a drug used for diabetes and weight management, reduced voluntary alcohol drinking in rats bred to prefer alcohol. Researchers tested three injected doses in male and female rats, finding greater reductions in drinking at higher doses. At the highest dose, rats undergoing withdrawal also showed fewer behaviors associated with anxiety. In rats without prior alcohol exposure, semaglutide reduced movement, blood glucose, fat mass, and certain brain signals that normally inhibit nerve activity. These findings support further investigation into whether semaglutide could help treat alcohol use disorder and related symptoms. However, animal behaviors do not establish benefits for human anxiety or withdrawal, and reduced movement complicates interpretation. This summary is based on the abstract only, which does not provide sample sizes or numerical effect estimates. Alcohol withdrawal requires medical assessment.
Detailed Summary
Alcohol use disorder can damage physical and mental health, making treatments that address both drinking and withdrawal symptoms valuable. Researchers tested whether semaglutide, a drug already used for diabetes and weight management, could reduce alcohol consumption and behaviors associated with anxiety in rats. This was not a study of treatment in humans.
The study used male and female rats selectively bred to prefer alcohol and show pronounced behaviors resembling anxiety and depression. Animals received semaglutide injections at three doses or a control injection. Researchers measured voluntary drinking with access to alcohol and water. They also assessed movement, anxiety, and stress during withdrawal and in rats without prior alcohol exposure.
Semaglutide reduced voluntary alcohol consumption, with larger reductions at higher doses. At the highest dose, treated rats showed less behavior associated with anxiety during withdrawal in an open arena test. In rats without prior alcohol exposure, the drug also reduced movement, blood glucose, and fat mass. The abstract provides no numerical estimates of these effects.
Brain measurements showed reduced inhibitory nerve signaling in a region of the frontal cortex involved in regulating behavior. These results suggest that semaglutide could influence alcohol consumption alongside emotional responses to withdrawal. However, the experiments do not establish that this signaling change caused either behavioral benefit.
These findings support further clinical research, not using semaglutide as a substitute for established alcohol treatment. Animal behavior does not directly measure human anxiety, and reduced movement complicates interpretation of behavioral tests. The abstract does not report sample sizes, treatment duration, or results separately for males and females. This summary is based on the abstract only, so detailed methods and statistical reliability could not be assessed. The study does not demonstrate improved lifespan or healthspan, and alcohol withdrawal in humans can be dangerous and requires medical assessment and appropriate care.
Key Findings
- Semaglutide reduced voluntary alcohol consumption in alcohol-preferring rats, with greater reductions at higher doses.
- The highest tested dose reduced anxiety-like behaviors during withdrawal in an open field test.
- In rats without prior alcohol exposure, semaglutide reduced movement, blood glucose, and fat mass.
- Semaglutide reduced inhibitory signaling in the infralimbic prefrontal cortex; its role in the behavioral effects remains uncertain.
- These animal findings support human research, not self-treatment of alcohol withdrawal with semaglutide.
Methodology
Male and female Marchigian Sardinian alcohol-preferring rats received subcutaneous semaglutide at 0.001, 0.01, or 0.1 mg/kg or vehicle, with voluntary drinking measured using a two-bottle choice test. Behavioral testing used the highest dose during withdrawal and in alcohol-naïve rats; additional experiments assessed inhibitory signaling in the central amygdala and infralimbic prefrontal cortex.
Study Limitations
This summary is based on the abstract only, which omits sample sizes, numerical effect estimates, treatment duration, and sex-specific results. A selectively bred rat model cannot establish human benefits, and reduced locomotion complicates interpretation of anxiety-related behavioral tests.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: